羟基脲治疗与撒哈拉以南非洲镰状细胞贫血儿童疟疾发病率降低相关
REACH研究在撒哈拉以南非洲4国为606例镰状细胞贫血儿童提供最大耐受剂量羟基脲,3387患者年治疗期间发生717次临床疟疾发作;校正分析显示中性粒细胞绝对计数每翻倍疟疾风险HR 1.37,中性粒细胞绝对计数<3.0×10⁹/L与疟疾发病率降低相关,脾肿大1-4 cm较不可触及脾脏疟疾风险HR 2.01。
要点
- 最大耐受剂量羟基脲治疗与镰状细胞贫血儿童疟疾发病率降低相关。
- 确诊疟疾感染多变量分析中,中性粒细胞绝对计数每翻倍HR 1.37(95%CI 1.10-1.70;P=.0052)。
- 中性粒细胞绝对计数<3.0×10⁹/L与疟疾发病率降低相关;脾肿大1-4 cm较不可触及脾脏HR 2.01(95%CI 1.41-2.85;P=.0001)。
核心结论
- 最大耐受剂量羟基脲通过尚未完全明确的机制与镰状细胞贫血儿童疟疾发病率降低相关,治疗相关的轻度骨髓抑制即中性粒细胞绝对计数<3.0×10⁹/L是有益的。
- 脾肿大是非洲镰状细胞贫血儿童疟疾感染的一个原因未明的危险因素。
研究设计与样本
- REACH研究(NCT01966731)在撒哈拉以南非洲(安哥拉、刚果民主共和国、肯尼亚和乌干达)所有临床中心为镰状细胞贫血儿童提供最大耐受剂量羟基脲。
- 采用改良Cox间隔时间模型估计基线人口学以及时变实验室和临床参数的风险比(HR)及95%置信区间(CI),用于重复事件分析。
- 共606例研究参与者,3387患者年的羟基脲治疗期间发生717次临床疟疾发作,涉及336例参与者。
主要发现
- 717次临床疟疾发作中超过半数经血涂片和/或快速诊断检测确认,其中97.8%为恶性疟原虫。
- 在限于每名儿童4次确诊感染的单变量分析中,疟疾风险与中性粒细胞绝对计数、脾肿大、血红蛋白和达到最大耐受剂量显著相关;年龄、疟疾季节、最大耐受剂量、胎儿血红蛋白、α-地中海贫血和葡萄糖-6-磷酸脱氢酶缺乏症无影响。
- 确诊感染的多变量回归中,中性粒细胞绝对计数显著(HR 1.37/每翻倍值;95%CI 1.10-1.70;P=.0052),中性粒细胞绝对计数<3.0×10⁹/L与疟疾发病率降低相关。
- 与不可触及脾脏相比,1-4 cm脾肿大与更高的疟疾风险相关(HR 2.01;95%CI 1.41-2.85;P=.0001)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Realizing Effectiveness Across Continents with Hydroxyurea (REACH, NCT01966731) provides hydroxyurea at maximum tolerated dose (MTD) for children with sickle cell anemia (SCA) in sub-Saharan Africa. Beyond reducing SCA-related clinical events, documented treatment benefits include ∼50% reduction in malaria incidence. To identify associations and propose mechanisms by which hydroxyurea could be associated with lower malaria rates, infections were recorded across all clinical sites (Angola, Democratic Republic of Congo, Kenya, and Uganda). Hazard ratios (HR) with 95% confidence intervals (CIs) for baseline demographics, and time-varying laboratory and clinical parameters were estimated in a modified Cox gap-time model for repeated events. Over 3387 patient-years of hydroxyurea treatment, 717 clinical malaria episodes occurred in 336 of 606 study participants; over half were confirmed by blood smear and/or rapid diagnostic testing with 97.8% Plasmodium falciparum. In univariate analysis limited to 4 confirmed infections per child, malaria risk was significantly associated with absolute neutrophil count (ANC), splenomegaly, hemoglobin, and achieving MTD; age, malaria season, MTD dose, fetal hemoglobin, α-thalassemia, and glucose-6-phosphate dehydrogenase deficiency had no effect. In multivariable regression of confirmed infections, ANC was significant (HR, 1.37 per doubled value; 95% CI, 1.10-1.70; P = .0052), and ANC values <3.0 × 109/L were associated with lower malaria incidence. Compared with nonpalpable spleen, 1- to 4-cm splenomegaly also was associated with higher malaria risk (HR, 2.01; 95% CI, 1.41-2.85; P = .0001). Hydroxyurea at MTD is associated with lower malaria incidence in SCA through incompletely defined mechanisms, but treatment-associated mild myelosuppression with ANC <3.0 × 109/L is salutary. Splenomegaly is an unexplained risk factor for malaria infections among children with SCA in Africa.
引用
- Olupot-Olupot P, Tomlinson G, Williams TN, et al. Hydroxyurea treatment is associated with lower malaria incidence in children with sickle cell anemia in sub-Saharan Africa. Blood. 2023. PMID: 36375125. doi:10.1182/blood.2022017051
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。